Intrasense — Regulatory Filings 2018

Nov 26, 2018

Press release Montpellier (France) - San Diego (USA), November 26, 2018 - 5:45 pm CET

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and creator of Myrian®, and 12 Sigma Technologies, a pioneer in introducing Artificial Intelligence and deep learning to medical diagnosis and data analysis, announce the strengthening of their multi-year partnership. The two companies are launching shared, innovative Artificial Intelligence on the European market. Their collaboration includes the commercialization of "σ-Discover Lung Nodule" in Europe, a revolutionary product for lung cancer detection based on Intrasense's Myrian® technologies and 12 Sigma's algorithmic expertise. Furthermore, the companies plan to launch a portfolio of unique Artificial Intelligence-based Computer Aided Diagnostics (CAD) solutions.

Exclusive distribution of Artificial Intelligence solutions in Europe

Already deployed at more than 200 sites in China and soon to be commercialized in the USA, European marketing and sales for the σ-Discover Lung Nodule software will now be supported by Intrasense.

Already regulatory-compliant in China, the product is currently being certified for the European market. Its commercialization take effect in the first half of 2019.

Thereafter, a complete common Artificial Intelligence solutions portfolio, developed hand in hand by both companies, will complete the offering.

As part of their first multi-year partnership contract signed in 2017, both partners are closely working together to launch the σ-Discover Lung Nodule technology developed by 12 Sigma Technologies using Myrian® platform with Myrian® Studio.

This application is a Computer Aided Diagnostics (CAD) system, based on Deep Learning technology and dedicated to facilitating analysis and diagnosis of lung nodules. Helping radiologists to detect and assess nodules, this highly innovative solution has been trained on a database of hundreds of thousands of exams. It is a world-leading technology, achieving unprecedented accuracy as a diagnosis tool. Further, the system compares and analyzes re-examination image series to automatically generate a structured report.

Its accurate detection and extraordinary thin segmentation, combined with extremely reliable reporting, positions σ-Discover Lung Nodule among the best analysis solutions in the world market.

Promising commercial prospects

After the USA, Europe is the second largest market for Artificial Intelligence, with +54% worldwide annual growth (source: IDC 2017). Commercialization of σ-Discover Lung Nodule on the European market and the portfolio of Artificial Intelligence products will be a major asset for selling the broader range of Myrian® applications.

Driven by the success of their common participation in the Journées Francophones de Radiologie congress last October in Paris (France), both partners will jointly participate in 2019 in the major European conferences to promote their solutions, starting next February in Vienna (Austria) at the European Congress of Radiology.

« We are happy and proud to play an active part in disseminating innovative Artificial Intelligence solutions in Europe, developed in association with 12 Sigma Technologies. With the strengthening of our partnership, we are increasing the portfolio of applications proposed to our partners and potential common targets: we benefit from a strong business collaboration and an additional competitive advantage in our markets, » commented Nicolas Reymond, Chief Executive Officer of Intrasense.

Xin Zhong, Chief Executive Officer and co-founder of 12 Sigma Technologies confirms: « After an encouraging start to commercialization in China this year, we are glad to maintain the expansion and commercialization of our innovations, leaning on a renowned European partner, and on a major market for the development of our company. 12 Sigma is pleased to reinforce this collaboration, started 18 months ago with Intrasense, in order to truly combine the competencies of both companies, each in their own field of expertise. »

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner, etc.). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 40 employees, among whom 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. For more information, please visit www.intrasense.fr.

About 12 Sigma Technologies

Founded in 2015, 12 Sigma Technologies is a pioneer in introducing artificial intelligence and deep learning technologies to modern medicine. The σ-DiscoverTM series, a portfolio of computer aided diagnosis (CAD) products based on AI, have been clinically proven to reduce radiologists' reading time while improving reading accuracy. Partnering with more than 30 top research hospitals across the globe, 12 Sigma has developed CAD products in lung cancer, lung diseases, liver cancer, breast cancer, brain tumors, stroke, bone fracture and more. The σ-DiscoverTM series has been deployed in 200+ healthcare institutions world-wide. Winner of "The 10 Most Innovative AI companies" award by X-techer, 12 Sigma has more than 80 employees in Research and Development, who are located in San Diego, Beijing, Suzhou and Shanghai. For more information, please visit www.12sigma.cn.

Contacts

Intrasense Nicolas Reymond Chief Executive Officer 1231 avenue du Mondial 98, 34000 Montpellier, FRANCE Tel: +334 67 130 130 investor@intrasense.fr

12 Sigma Technologies Xin Zhong Chief Executive Officer 11975 El Camino Real, Suite 102, San Diego, CA, 92130, USA Tel: +1 858 412 3455 contact@12sigma.ai

NewCap Investor Relations and Financial Communication Valentine Brouchot Pierre Laurent

Tel: +331 44 71 94 96 intrasense@newcap.eu